Primary blasts of a t(11;17)(q23;q21) acute promyelocytic leukaemia (APL) patient were analysed with respect to retinoic acid (RA) and arsenic trioxide (As 2 O 3 ) sensitivity as well as PLZF/RARa status. Although RA induced partial monocytic dierentiation ex vivo, but not in vivo, As203 failed to induce apoptosis in culture, contrasting with t(15;17) APL and arguing against the clinical use of As203 in t(11;17)(q23;q21) APL. Prior to cell culture, PLZF/RARa was found to exactly co-localize with PML onto PML nuclear bodies. However upon cell culture, it quickly shifted towards microspeckles, its localization found in transfection experiments. Arsenic trioxide, known to induce aggregation of PML nuclear bodies, left the microspeckled PLZF/RARa localization completely unaected. RA treatment led to PLZF/RARa degradation. However, this complete PLZF/RARa degradation was not accompanied by dierentiation or apoptosis, which could suggest a contribution of the reciprocal RARa/PLZF fusion product in leukaemogenesis or the existence of irreversible changes induced by the chimera.
Primary blasts of a t(11;17)(q23;q21) acute promyelocytic leukaemia (APL) patient were analysed with respect to retinoic acid (RA) and arsenic trioxide (As 2 O 3 ) sensitivity as well as PLZF/RARa status. Although RA induced partial monocytic dierentiation ex vivo, but not in vivo, As203 failed to induce apoptosis in culture, contrasting with t(15;17) APL and arguing against the clinical use of As203 in t(11;17)(q23;q21) APL. Prior to cell culture, PLZF/RARa was found to exactly co-localize with PML onto PML nuclear bodies. However upon cell culture, it quickly shifted towards microspeckles, its localization found in transfection experiments. Arsenic trioxide, known to induce aggregation of PML nuclear bodies, left the microspeckled PLZF/RARa localization completely unaected. RA treatment led to PLZF/RARa degradation. However, this complete PLZF/RARa degradation was not accompanied by dierentiation or apoptosis, which could suggest a contribution of the reciprocal RARa/PLZF fusion product in leukaemogenesis or the existence of irreversible changes induced by the chimera. Keywords: nuclear dot; leukaemia; degradation; PML; t(15;17); translocation Acute promyelocytic leukaemia (APL)-like syndromes are characterized by four types of reciprocal translocations all implicating the retinoic acid receptor a (RARa). The most common t(15;17)(q21-q11-22) translocation links the PML growth suppressor to the RARa gene, leading to a transforming fusion protein, PML/RARa (Borrow et al., 1990; de TheÂ et al., 1990 de TheÂ et al., , 1991 Kakizuka et al., 1991; Pandol® et al., 1991; Kastner et al., 1992) . PML is an interferon-induced gene coding for a protein localized onto nuclear organelles of unknown function, PML nuclear bodies (Daniel et al., 1993; Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994; Stadler et al., 1995) . Overexpression of PML causes cell growth retardation and reverts transformation by several oncogenes (Mu et al., 1994; . Formation of PML-PML/RARa heterodimers is responsible for the shift of PML and associated proteins from the normal speckled localization to the microspeckled pattern in t(15;17) APL cells, a phenomenon proposed to abrogate PMLmediated growth-suppression (Mu et al., 1994) . Remarkably, clinical remission of t(15;17) APL patients can be obtained with either of two compounds, all-trans retinoic acid (RA) and arsenic trioxide (As 2 O 3 ) (Huang et al., 1988; Degos, 1993; Chen et al., 1996 Chen et al., , 1997a . Both drugs were shown to lead to speci®c degradation of the PML/RARa fusion product which is associated to granulocytic differentiation and/or apoptosis of the malignant cells (Raelson et al., 1996; Yoshida et al., 1996; . While RA targets the RARa moiety of the fusionprotein, As 2 O 3 targets its PML part, providing the ®rst example of oncogene targeted therapies .
The three other APL-associated translocations, t(5;17)(q35;q21), t(11;17)(q23;q21), and t(11;17) (q13;q21), fuse nucleophosmin (NPM), promyelocytic leukaemia zinc ®nger (PLZF), and nuclear mitotic apparatus (NuMA) genes to RARa, respectively (Chen et al., 1993; Campbell et al., 1994; Redner et al., 1996; Wells et al., 1997) . Although all four fusion proteins harbour identical RARa sequences (including the DNA binding region (C) and the ligand binding region (E)) and all have an N-terminal dimerization interface provided by the fusion partner, their clinical behaviour during RA therapy is dierent. The classical t(15;17) APL as well as the t(5;17) and t(11;17)(q13;q21) patients respond well to RA treatment, whereas the t(11;17)(q23;q21) cases were reported not to respond to RA (Licht et al., 1995; Redner et al., 1996; Wells et al., 1997) . Thus far this dierence was attributed to the divergent N-terminal fusion partners. Through its POZ domain, PLZF is a transcriptional repressor (Li et al., 1997) , and was recently shown to bind the SMRT co-repressor (Dhordain et al., 1997; Hong et al., 1997) . PLZF, like PML, displays growth suppressive properties and has a nuclear speckled localization, which upon fusion to RARa becomes microspeckled . Moreover, PML and PLZF interact directly with each other, providing unexpected similarities between t(11;17) and t(15;17) cases.
Here, we demonstrate that, in vitro cells from a single t(11;17)(q23;q21) patient underwent a slight dierentiation towards the monocytic lineage in response to RA, despite resistance to in vivo RA therapy, but failed to respond to arsenic trioxide. The PLZF/RARa fusion product was degraded upon in vitro RA treatment. Analysis of PLZF/RARa and PML localization in response to RA, As 2 O 3 or IFN was consistent with that previously reported in transfected cells . In contrast to the t(15;17) APL patients where the PML/RARa protein is responsible for the disease, our results suggest that the situation in t(11;17) cases is more complex, as complete PLZF/RARa degradation does not result in a reversal of the leukaemic state. To strengthen these data, surface markers speci®c for dierentiation towards the granulocytic or monocytic lineage were examined on the same samples. As can be seen in Table 1 , RA treatment induced an increased expression of markers for either granulocytic maturation (CD11b, CD11c) or monocyte-macrophage dierentiation (CD14, CD11b). A signi®cative increase of NBT reduction was also observed. As 2 O 3 treatment led to increased expression of CD11c, while CD11b, CD14, and NBT levels were down-regulated or remained unchanged. These ®ndings indicate that t(11;17) cells dierentiate towards the monocytic , had no eect on dierentiation or surface marker expression.
Results

RA, but not As
Immuno¯uorescence of t(11;17) cells treated with RA or As 2 O 3 in vitro In uncultured cells, the PLZF/RARa protein is localized onto large nuclear bodies (Figure 2 : uncultured). However, 4 h of culture caused a massive change in the immuno¯uorescence pattern, as both anti-PLZF and anti-RARa antibodies now detected microspeckles which resemble the PML/ RARa pattern (Figure 2 : day 1 and day 5, untreated). These changes progressed up to 5 days of culture. The absence of a PLZF-or PLZF/RARaspeci®c antibody precluded a more detailed analysis of the behaviour of the wild type protein. To check whether the change in immuno¯uorescence pattern upon cell culture occurs in all types of APL cells, the same experiment was performed with primary t(15;17) cells. In contrast to the t(11;17) patient's cells, these uncultured blasts showed the characteristic microspeckles, and this pattern was not changed by subsequent cell culture (not shown).
After 4 h of in vitro RA treatment, the PLZF/ RARa¯uorescence diminishes to become undetectable after 24 h (Figure 2 : day 1, RA). As 2 O 3 treatment, recently shown to degrade speci®cally the PML/RARa fusion protein in t(15;17) APLs , had no eect on the PLZF/ RARa fusion product (Figure 2: day 1, As 2 O 3 ) . Interferon, which we previously showed to increase the intensity of the speckled PLZF¯uorescence by a PML-triggered recruitment mechanism , here again increased the speckled¯uorescence in the patient's cells, likely re¯ecting an enhanced association between the diuse nuclear PLZF and the PML dots (Figure 2: day 1, IFN) .
When we examined the same cytospins with an anti-PML polyclonal antibody, a complete colocalization between PLZF/RARa and PML bodies was observed in the uncultured sample (Figure 2 : right column, uncultured). However, 4 h of cell culture were enough for PLZF/RARa to become progressively micropunctuated, whereas PML remained onto PML bodies throughout the 5 days (Figure 2 : right column, day 1). Thus, as previously shown in transfected cells, the PLZF/RARa fusion has no dominant eects on the normal localization of PML . Finally, although As 2 O 3 induced the aggregation of PML bodies, it had no eect on either the abundance of PLZF/RARa or its intracellular localization (Figure 2: right column, As 2 O 3 ).
RA, and not As 2 O 3 , induces the degradation of the PLZF/RARa fusion protein
Western blot analysis (Figure 3 ) with a polyclonal rabbit anti-RARa antibody revealed the presence of the PLZF/RARa fusion protein in the untreated or As 2 O 3 treated samples, while in the RA-treated cells the fusion protein was lost, consistent with the¯uorescence data.
Discussion
The data presented here demonstrate that the t(11;17)(q23;q21) APL-like cases dier from the classical t(15;17) APL patients, not only in their sensitivity to RA or arsenic trioxide therapy, but also in the signi®cance of treatment-induced degradation of the fusion product. These results strengthen and extend our previous data obtained with transfected cells where PLZF/RARa was found to display a dominant eect on the localization of wild type PLZF, but not on PML . The data obtained from this patient do not favour the use of As 2 O 3 in the clinical management of t(11;17)(q23;q21) APL.
The PLZF/RARa protein is detected here for the ®rst time in patient's cells by Western blot analysis. Interestingly, we ®nd that the pro®le of PLZF/RARa expression is highly dependent upon the culture conditions: the fusion is localized onto PML nuclear bodies before exposure to serum and then shifts onto microspeckles. Several hypotheses could be put forward to account for these ®ndings. The amount of the native PLZF protein, which could theoretically bridge PML and PLZF/RARa might be downregulated by serum exposure. Indeed, in primary cells, the normal PLZF is easily detected on PML nuclear bodies, while detection of the NB-associated form of PLZF is dicult in most other cell-lines (data not shown). This may either re¯ect dierences in PLZF quantities, or dierences in its ability to be targeted onto PML NBs . Such serum dependence is consistent with PLZF being a potent growth suppressor (Zelent and Licht, unpublished results), possibly through its transcription repressor activity. Alternatively, serum could directly act on the PLZF/RARa fusion, possibly through control of its phosphorylation.
We show that arsenic trioxide, which induces apoptosis of t(15;17) cells (Chen et al., , 1997a and degrades PML/RARa through the speci®c targeting of its PML moiety, has no eect on PLZF/ RARa abundance and localization. Similarly, As 2 O 3 had no obvious eect on dierentiation or apoptosis. This is not surprising, taken into account the speci®c targeting of PML by As 2 O 3 and the absence of apparent direct interaction between PML and PLZF/ RARa Zhu et al., 1997) . Nevertheless, in the patient's cells, the fusion product, PLZF/RARa, is speci®cally degraded by retinoic acid, consistent with our previous observation in transfected cells . Paradoxically, contrarily to the situation encountered with the t(15;17) patients, degradation of the fusion protein did not cause any major changes in the patient's cells. Indeed, this patient was clinically resistant and showed only an incomplete The PLZF/RARa protein is indicated by an arrow. CBB represents a segment of the Coomassie Brilliant Blue stained gel to serve as loading control monocytic dierentiation in culture. This differentiation might result from the degradation of the chimeric protein, similar to that observed in NB4 cells where 10 77 M arsenic trioxide degrades PML/RARa and triggers a partial dierentiation (Chen et al., 1997a; Zhu et al., 1997) .
To account for this paradox three hypotheses could be proposed. PLZF/RARa may play no direct role in the leukaemogenesis which is very unlikely for a protein present in all t(11;17) APLs, shown to interfere with nuclear receptor response (Dong et al., 1996) and which induces leukaemia in transgenic mice (He et al., 1997) . A second possibility could be that PLZF/RARa is associated with irreversible changes, and is no longer implicated in the maintenance of the leukaemic state. Note in this respect that PLZF was shown to speci®cally bind the N-Cor and SMRT co-repressors (Dhordain et al., 1997; Hong et al., 1997) . These proteins recruit histone deacetylase complexes and could induce irreversible changes in the chromatin state (Chen et al., 1997b; Nagy et al., 1997; Grignani et al., 1998; Guidez et al., 1998; Lin et al., 1998) . The third explanation is an implication of the reciprocal RARa/PLZF product, whose mRNA is found in all t(11;17) patients. This putative reciprocal fusion protein contains the ®ve C-terminal zinc ®ngers, was recently shown to be transforming and to bind DNA (Li et al., 1997; Sitterlin et al., 1997) , and could thus, through competition with wild type PLZF, alter normal PLZF function. Indeed, normal PLZF could be delocalized by either PLZF/RARa or PML/RARa; in the t(11;17) cases, the few normal PLZF polypeptides which are not trapped by PLZF/ RARa could be chased from their recognition sites by RARa/PLZF. Such a model, stressing the importance of deregulation of PLZF, could again reunify the t(15;17) and t(11;17) APL pathogenesis .
Materials and methods
Patient
The patient was previously reported elsewhere (Licht et al., 1995) but was in relapse after a remarkable 3 years complete remission. RA therapy was ®rst tried after the diagnosis but ineective, which was further explained by the cytogenetical and molecular data (Licht et al., 1995) . A bone marrow aspiration was performed with informed consent from the patient to test whether the blast cells were arsenic trioxide-sensitive. After the obtention of the in vitro data described here, showing a slight monocytic differentiation, RA treatment was resumed without any signi®cant change in the peripheral blood cell counts.
Cell culture
After bone marrow puncture, patient cells were directly taken up in RPMI medium 50% FCS. Immediately after a Ficoll-Hypaque centrifugation was performed to remove erythocytes, and cytospins were prepared from this sample. May-GruÈ nwald-Giemsa staining revealed 90% of blast cells. Subsequently, cells were diluted to about 15610 6 cells/ml in RPMI medium supplemented with 15% FCS, glutamine, essential amino acids, sodium pyruvate, penicillin and streptomycin.
Retinoic acid and As 2 O 3 were purchased from Sigma, and used in a ®nal concentration of 10 76 M. IFNa was used at a concentration of 1000 IU/ml.
Antibodies
A mouse monoclonal antibody against PLZF was used at an 1 : 100 dilution (Shaknovich, Waxman, and Zelent, unpublished results). The polyclonal rabbit anti-PLZF antibody was used in an 1 : 500 dilution for Western blot analysis (Shaknovich, Waxman and Zelent, unpublished results). The polyclonal rabbit anti-RARa antibody, RPaF', was kindly provided by P Chambon, and used at an 1 : 4000 (Western blot analysis) dilution. The monoclonal antibody, RARa4-H1A1, kindly provided by B Allegretto, was used in an 1 : 500 dilution (immunofluorescence). The PML polyclonal rabbit antibody was used in an 1 : 400 dilution as previously described (Daniel et al., 1993) . Secondary antibodies (FITC, Texas-Red or peroxidase labelled) were purchased from Biosys or Serotec.
Immuno¯uorescence and Western blot analysis
Immuno¯uorescence was performed as described previously. In short, cytospins were air-dried for at least 1 h, ®xed in 4% PFA for 10 min at 48C, washed extensively in TBS, and blocked in TBS 10% horse serum. The ®rst antibody was diluted in TBS 10% horse serum, and incubated for 3 h at 378C, washed in TBS, and the secondary antibody was added in TBS. Confocal analysis and Western blot analysis were done as described (Koken et al., 1994) .
